The Asia Pacific late-stage chronic kidney disease drugs market is expected to reach US$ 4,904.81 million by 2027 from US$ 2,036.47 million in 2019; the market is estimated to grow at a CAGR of 12.2 % from 2020 to 2027.
The high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policies for the late stage chronic kidney disease treatments are among the prime factors furling the market growth in this region. However, delay in the diagnosis of chronic kidney disease hampers the growth of the market.
In late-stage renal disease, kidneys lose their ability to filter waste and excess fluid from blood, which leads to waste accumulation in the body. Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. As per data published by India Today, on March 14, 2019, more than 100,000 patients are diagnosed with end-stage kidney disease (ESKD) in India every year, and the number of people opting for the treatment for the same is expected to increase with the mounting awareness regarding this condition. Besides, the rising prevalence of hypertension and diabetes is a major cause of the progression of end-stage kidney disease (ESKD). These factors are expected to enhance market growth during the forecast period. Furthermore, various strategies put forth by the World Health Organisation (WHO) to help policymakers in developing suitable policies, entailing the vital medicine list concept and the universal health coverage (UHC) approach, would boost the market growth in the coming years.
The COVID-19 pandemic has negatively impacted Asia Pacific late-stage chronic kidney disease drugs market. Elderly people and kidney disease patients seem to be at higher risk for more serious COVID-19 illness. However, Nephrology societies have made suggestions and provided guidelines to prevent COVID-19 transmission in dialysis facilities and to provide emergency services for patients. Therefore, the Asia Pacificlate-stage chronic kidney disease drugs market is expected to regain traction in the coming months.
On the basis of product type, the Asia Pacificlate-stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the largest share of the market in 2019, and it is expected to register the highest CAGR during the forecast period.
The Asia Pacificlate stage chronic kidney disease drugs market, based on Indication, is segmented into late stage chronic kidney disease induced hyperparathyroidism, late stage chronic kidney disease induced hyperphosphatemia, and late stage chronic kidney disease induced hyperkalemia. The late-stage chronic kidney disease induced hyperparathyroidism segment held the largest market share in 2019, and it is further expected to register the highest CAGR during 2020–2027.
The Asia Pacificlate-stage chronic kidney disease drugs market, by distribution channel, is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest share of the market in 2019. However, the market for online pharmacies is estimated to witness the highest CAGR during the forecast period.
A few of the primary and secondary sources associated with report on the Asia Pacificlate-stage chronic kidney disease drugs market are the Australian Institute of Health and Welfare (AHIW), Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH).